RE: Directors cut4 Jun 2024 09:22
Solow ... We know that there is enough money from the raise to hopefully get initial trial results. If those results are positive and that's why we are all now waiting, this will not be a £20m MCAP company but more like a £100m - £200m company i.e. between 7p and 20p a share. At that point, raising £6m will be easy and will mean hardly any dilution.
Like all small pharma, its about risk and reward. Those that take a risk and get in now could be getting multiples of today but its a risk since we don't really know whats happening in the background OR you wait for results and then buy in much higher with less reward but less stress. Depends on the type of investor you are I guess.